Bank of America
SCNI

Bank of America’s Scinai Immunotherapeutics SCNI Stock Holding History

Bank of America’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$278 – 8379
2024
Q2 		$278 Buy
+100
New +$415 ﹤0.01% 7486
2021
Q4 		– Sell
-4
Closed -$1K – 8588
2021
Q3 		$1K Buy
+4
New +$1.03K ﹤0.01% 8003
2017
Q3 		– Hold
0
– – – 7238
2017
Q2 		– Hold
0
– – – 7143
2017
Q1 		– Hold
0
– – – 7194

Other funds holding SCNI

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's SCNI Position: Q3 2024 in Review

Bank of America sold out of Scinai Immunotherapeutics (SCNI) in Q3 2024, closing a stake of 100 shares — an estimated $278 sold.

Bank of America first reported a position in SCNI in Q3 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 5 funds tracked by Wall St. Rank hold SCNI as of Q3 2024.

  • Bank of America reported no remaining Scinai Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Bank of America sold 100 Scinai Immunotherapeutics shares in Q3 2024, an estimated $278.
  • Bank of America first reported a position in Scinai Immunotherapeutics in Q3 2021 and held it in 2 quarters.
  • Bank of America's Scinai Immunotherapeutics position peaked at $1K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.